↓ Skip to main content

Omission of Upfront Craniospinal Irradiation in Patients with Low-Risk WNT-Pathway Medulloblastoma Is Associated with Unacceptably High Risk of Neuraxial Failure

Overview of attention for article published in Clinical Cancer Research, June 2022
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (92nd percentile)
  • Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

twitter
33 tweeters

Readers on

mendeley
2 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Omission of Upfront Craniospinal Irradiation in Patients with Low-Risk WNT-Pathway Medulloblastoma Is Associated with Unacceptably High Risk of Neuraxial Failure
Published in
Clinical Cancer Research, June 2022
DOI 10.1158/1078-0432.ccr-22-0758
Pubmed ID
Authors

Tejpal Gupta, Shizan Pervez, Archya Dasgupta, Abhishek Chatterjee, Sridhar Epari, Girish Chinnaswamy, Rakesh Jalali

Abstract

Medulloblastoma is a heterogenous disease comprising four molecular subgroups - wingless (WNT), sonic hedgehog (SHH), Group 3, and Group 4 respectively. Excellent long term outcomes have prompted de-intensification of therapy in WNT-pathway medulloblastoma. We assessed safety of avoiding upfront craniospinal irradiation (CSI) in children with low-risk WNT-pathway medulloblastoma. Children with low-risk WNT-pathway medulloblastoma were treated with post-operative focal conformal radiotherapy avoiding upfront CSI followed by 6 cycles of adjuvant systemic chemotherapy. A group-sequential design (triangular test) with pre-defined stopping rules if the rate of relapse exceeded 15% at 2 years was incorporated to ensure safety of study participants. Seven children with low-risk WNT-pathway medulloblastoma were accrued after written informed consent/assent and treated as per protocol. One child succumbed to neutropenic sepsis and multi-organ dysfunction during chemotherapy. Three children were detected with neuraxial failure (supratentorial brain and/or spine) on surveillance neuro-imaging within 2 years from index diagnosis leading to premature study termination. At relapse, children were treated with salvage CSI plus boost irradiation of metastatic deposits followed by second line chemotherapy. Two of them continue to be in remission (32 and 26 months after first relapse) while one child developed second relapse necessitating further systemic chemotherapy and craniospinal re-irradiation resulting in excellent clinico-radiological response. At a median follow-up of 42 months, the 2 year Kaplan-Meier estimates of event-free survival, recurrence-free survival and overall survival were 42.9%, 50% and 85.7% respectively. Omission of upfront CSI in low-risk WNT-pathway medulloblastoma is associated with unacceptably high risk of neuraxial failure.

Twitter Demographics

The data shown below were collected from the profiles of 33 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 2 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 2 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 2 100%
Readers by discipline Count As %
Unspecified 1 50%
Biochemistry, Genetics and Molecular Biology 1 50%

Attention Score in Context

This research output has an Altmetric Attention Score of 23. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 June 2022.
All research outputs
#1,307,797
of 21,479,159 outputs
Outputs from Clinical Cancer Research
#947
of 12,210 outputs
Outputs of similar age
#22,601
of 284,032 outputs
Outputs of similar age from Clinical Cancer Research
#25
of 116 outputs
Altmetric has tracked 21,479,159 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,210 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.2. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 284,032 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 116 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 79% of its contemporaries.